The SEC asks Novartis, ‘Haven't we met before?’

After settling an FCPA enforcement brought by the SEC in March, Novartis is now under criminal investigation in South Korea for alleged illegal payments to physcians. Should the SEC reopen its investigation?

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.